Stay updated on Safety of Single Dose UB-221 in Urticaria Clinical Trial
Sign up to get notified when there's something new on the Safety of Single Dose UB-221 in Urticaria Clinical Trial page.

Latest updates to the Safety of Single Dose UB-221 in Urticaria Clinical Trial page
- CheckyesterdayChange DetectedThe study record's revision history now shows a new revision label v3.5.4, replacing the previous v3.5.3, indicating an updated version of the page.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page footer site revision/version was updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check30 days agoChange DetectedThe revision label was updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check59 days agoChange DetectedRevision v3.5.0 was added and v3.4.3 removed, reflecting an update to the study protocol version.SummaryDifference0.1%

- Check66 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a maintenance/versioning update that does not modify the study details or other substantive content on the page.SummaryDifference0.1%

- Check95 days agoChange DetectedRevision: v3.4.2 was added and the funding-lapse notice (v3.4.1) was removed. There are no changes to the core study details, eligibility criteria, or outcomes.SummaryDifference0.5%

Stay in the know with updates to Safety of Single Dose UB-221 in Urticaria Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Single Dose UB-221 in Urticaria Clinical Trial page.